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Introduction {#sec001}
============

Hydrogen sulfide (H~2~S) is one of the three molecules (along with nitric oxide and carbon monoxide) most recently identified as gasotransmitters \[[@pone.0194176.ref001]\]. Despite its toxicity, it is recognised as an endogenously produced gaseous signalling molecule that induces a variety of beneficial reactions in cardiovascular tissues \[[@pone.0194176.ref002]\]. H~2~S activity upregulates such physiological properties as vasodilation, anti-inflammation, anti-oxidation and angiogenesis \[[@pone.0194176.ref003]\]. In addition, accumulating evidence suggests an association between atherosclerosis and deficiency in vascular cystathionine γ-lyase (CSE), an enzyme responsible for endogenous H~2~S production. It was shown by using CSE knockout mice that CSE gene deletion led to a decrease in H~2~S production with accelerated atherosclerosis \[[@pone.0194176.ref004]\]. Atherosclerotic plaques could also be ameliorated by overexpression of CSE in apolipoprotein E knockout (ApoE KO) mice \[[@pone.0194176.ref005]\] and H~2~S supplementation by exogenous H~2~S donors such as NaHS \[[@pone.0194176.ref006]\] and GYY4137 \[[@pone.0194176.ref007]\]. H~2~S is therefore suggested as an anti-atherogenic molecule. However, the mechanism by which H~2~S reduces atherosclerosis is still not clear.

Recently, H~2~S signalling through *S*-sulfhydration has been reviewed, and *S*-sulfhydration has been recognised as a key mechanism of H~2~S physiology \[[@pone.0194176.ref008]\]. Similar to *S*-nitrosylation, *S*-sulfhydration can cause post-translational modification of proteins \[[@pone.0194176.ref009]\]. *S*-sulfhydration takes place at reactive cysteine residues in proteins and results in the conversion of an--SH group of cysteine to an--SSH group. This conversion occurs in many proteins and modulates the functions of a targeted protein \[[@pone.0194176.ref009]\]. For example, H~2~S was shown to protect gastric epithelial cells from ischemia-reperfusion injury by Keap1 sulfhydration and further Keap1/Nrf2 disassociation and enhancement of Nrf2 nuclear translocation, which eventually attenuated oxidative stress and protected against mucosal injury \[[@pone.0194176.ref010]\]. Recently, H~2~S was suggested to inhibit the development of atherosclerosis through upregulating protein *S*-nitrosylation, thereby inhibiting the proliferation and migration of vascular smooth muscle cells \[[@pone.0194176.ref011]\]. Cystathionine β-synthase (CBS), another H~2~S-producing enzyme, was found to regulate endothelial function via protein *S*-sulfhydration, maintaining vascular health and function \[[@pone.0194176.ref012]\]. All these observations suggest the potential value of investigating *S*-sulfhydration in the context of atherosclerosis.

H~2~S signalling via *S*-sulfhydration is still not fully elucidated, in that only a few proteins have been identified to be *S*-sulfhydrated by H~2~S. To investigate H~2~S signalling in atherosclerosis, meta-analysis of *S*-sulfhydrated proteins in aortic proteins is the main step to be examined. Here we explore *S*-sulfhydrated proteins in aortic tissues of ApoE KO mice on an atherogenic diet and H~2~S treatment. We detected *S*-sulfhydration by modified biotin switch assay coupled with advanced proteomic identification strategies and analysed altered *S*-sulfhydration levels of proteins. Potential targets of protein *S*-sulfhydration were identified in aortic tissue. The difference in *S*-sulfhydration levels of proteins in aortic tissue indicates the possibility of functional alteration as well as disease-related consequences.

Materials and methods {#sec002}
=====================

Animals and experimental design {#sec003}
-------------------------------

Male wild-type C57BL/6J mice (WT) and ApoE KO mice were used in this study. All mice were housed in a controlled environment with free access to water and food on a 12-h light/dark cycle. WT mice were used as a reference of healthy mice without atherosclerosis. Atherosclerotic mice, ApoE KO mice were treated with or without H~2~S in the experiment. Briefly, they were fed a normal diet until 8 weeks of age and then switched to an atherogenic diet. After 4 weeks of the atherogenic diet, the ApoE KO mice were divided into two groups: vehicle control treatment with normal saline and H~2~S treatment with GYY4137 (Cayman Chemical Co., Ann Arbor, MI, USA), a novel H~2~S donor \[[@pone.0194176.ref013]\]. The H~2~S supplement experiment consisted of daily IP injection of GYY4137 (133 μmol/kg body weight for 4 weeks of atherogenic diet feeding) in the ApoE KO mice. Control ApoE KO mice were injected with normal saline alone. Body weights of mice were recorded weekly. Food uptake per mouse per day was calculated as follows: \[total food intake per cage\]/\[mice per cage\]/\[days of food consumption\]. After 4 weeks of treatment, all mice were sacrificed by using slow fill carbon dioxide asphyxiation. Non-clotted blood was collected from each mouse. Aortic tissues were excised, immediately frozen in liquid nitrogen and stored at --80°C until further processing. All animal experiments were approved by the Animal Experimentation Ethics Committee (AEEC) of the Chinese University of Hong Kong (CUHK) and in accordance with the Animals (Control of Experiments) Ordinance (Cap. 340) licensed from the Hong Kong Government Department of Health. They were performed conform the university's regulations on Use of Experimental Animals which incorporate The International Guiding Principles for Biomedical Research Involving Animals and The Hong Kong Code of Practice for Care and Use of Animals for Experimental Purposes.

Release of H~2~S in plasma and tissues after GYY4137 treatment {#sec004}
--------------------------------------------------------------

To detect H~2~S concentration *in vivo* after GYY4137 treatment, tissues (liver and kidney) and blood were collected at timed intervals (0 to 8 hours). H~2~S level in tissue homogenates was measured by zinc acetate assay as described previously with some modifications \[[@pone.0194176.ref013]\]. Briefly, liver and kidney were homogenized in ice-cold 100 mM potassium phosphate buffer (pH 7.4). L-cysteine (10 mM; 20 μl), pyridoxal 5'-phosphate (2 mM; 20 μl) and saline (30 μl) were added into the homogenate (430 μl). After incubation at 37°C for 30 min, zinc acetate (1% w/v, 250 μl) was injected to trap-generated H~2~S followed by trichloroacetic acid (10% w/v, 250 μl) to precipitate protein and thus stop the reaction. Subsequently, N,N-dimethyl-p-phenylenediamine sulfate (20 μM; 133 μl) in 7.2 M HCl was added followed by FeCl~3~ (30 μM; 133 μl) in 1.2 M HCl. After 15 min, absorbance at 670 nm was measured with a microplate reader (Bio-Tek Instrument INC., Rockville, MD, USA). Aliquots (500 μl) of mouse plasma were tested for H~2~S using the same procedure. All standards and samples were assayed in duplicate. The calibration curve of absorbance versus H~2~S concentration was obtained by using NaHS solution of varying concentrations (10 to 160 μm).

Quantitation of atherosclerotic plaque {#sec005}
--------------------------------------

Quantitation of atherosclerotic plaque was carried out as previously reported \[[@pone.0194176.ref005]\]. In brief, atherosclerotic lesions in the aortic root were examined at three location levels, and nine serial sections were prepared from each location. Sections from three locations were selected and stained with oil red O and counterstained with Mayer's hematoxylin. The images were then produced using an inverted microscope (Olympus IX-83, Tokyo, Japan). Histological staining in all images was quantified using ImageJ, and the mean staining within the aortic root of each mouse was obtained.

Detection of S-sulfhydration by modified biotin switch assay {#sec006}
------------------------------------------------------------

The assay was carried out with modifications according to Mustafa *et al*. \[[@pone.0194176.ref008]\]. Control and H~2~S-treated ApoE KO mice aortas were homogenised in HENS buffer \[250 mM HEPES-NaOH (pH 7.7), 1 mM EDTA, and 0.1 mM neocuproine\] supplemented with 100 μM deferoxamine and centrifuged at 13,000 *g* for 30 min at 4°C. Aorta homogenates were added to blocking buffer \[HENS buffer adjusted to 2.5% sodium dodecyl sulfate (SDS) and 20 mM methyl methanethiosulfonate (MMTS)\] at 50°C for 30 min with rotation. MMTS was removed by acetone, and the proteins were precipitated at --20°C for 30 min. After acetone removal, the proteins were resuspended in HENS buffer with 1% SDS and then incubated for 3 h at room temperature with biotin-HPDP in dimethyl sulfoxide without ascorbic acid, centrifuged, and resuspended in HENS buffer. The biotinylated and *S*-sulfhydrated proteins were pulled down by streptavidin beads. To detect biotinylated proteins, samples were separated on 12% SDS-PAGE gels, transferred to a polyvinylidene difluoride (PVDF) membrane, blocked with 5% non-fat milk, and incubated with streptavidin-peroxidase diluted 1:2000 for 1 h. The biotinylated proteins were also subjected to western blotting analysis using anti-glutathione peroxidase 1 (anti-GPx1) antibody (Abcam, Cambridge, UK).

In-gel tryptic digestion {#sec007}
------------------------

The biotinylated proteins were separated on a 12% SDS polyacrylamide gel (SDS-PAGE) and stained with coomassie blue. The gel lanes were cut into three slices. Each slice was further cut into 1x1 to 2x2-mm pieces, which were then placed into a 1.5 mL tube. The gel pieces were destained two to three times with destaining solution (50% acetonitrile, 25 mM ammonium bicarbonate). After in-gel reduction (10 mM dithiothreitol, 45 min, 56°C) and alkylation (11 mM iodoacetamide, 45 min in dark), gel pieces were shrunk in acetonitrite and dried down. Each gel slice sample was rehydrated by 0.3 μg trypsin in 25 mM ammonium bicarbonate and incubated overnight at 37°C. After that, the reaction was stopped with 1% trifluoroacetic acid. Peptides were extracted from gel pieces with incubation in extraction buffer (50% acetonitrile, 1% trifluoroacetic acid). The supernatant from all the fractions of the same sample were pooled and dried using a Speedvac.

Mass spectrometry analysis and protein identification {#sec008}
-----------------------------------------------------

The peptides were dissolved in a solution of 1% formic acid in water and injected onto an LC/MS system consisting of a Dionex Ultimate 3000 nano-LC system (Thermo Fisher Scientific Inc., Germany) associated with fraction collector, Proteineer fcII (Bruker Daltonics, Bremen, Germany) to fractionate and spot fractions onto MALDI target plates for protein identification for matrix-assisted laser desorption/ionisation. Mass spectrometry analyses were carried out on an UltrafleXtreme MALDI TOF/TOF analyser (Bruker Daltonics; Bremen, Germany). The database search was done using the Mascot search engine (Matrix Science Mascot 2.4.1) on the SwissProt databases (545536 sequences). The following parameters were used: up to 1 miss cleavages; MS tolerance 50 ppm; MSMS tolerance 0.5 Da; full tryptic peptides; partial modifications carbamidomethylation (C), oxidation (M); MudPIT scoring; significance threshold *P* \< 0.05. Protein identifications were validated only if they satisfied three requirements: (i) their score was significant (*P* \< 0.05) with cut-off criteria; (ii) they were identified with three peptides with score \>70; and (iii) they were identified in at least two out of the three runs.

Gene ontology (GO) and enrichment analysis in the protein data set {#sec009}
------------------------------------------------------------------

To determine GO annotations for selected proteins, we used the Database for Annotation, Visualization and Integrated Discovery (DAVID) (<https://david.ncifcrf.gov/>; version 6.8) to access a relational database of gene functional annotations \[[@pone.0194176.ref014],[@pone.0194176.ref015]\]. For the enrichment analysis, Protein ANalysis THrough Evolutionary Relationships (PANTHER) classification ([http://geneontology.org](http://geneontology.org/); version 11.1) was performed to investigate the enrichment of molecular function, biological process and protein class associated with each identified protein \[[@pone.0194176.ref016]\]. Enriched pathways were analysed by KEGG pathway analysis using WEB-based Gene SeT AnaLysis Toolkit (WEBGESTALT) (<http://www.webgestalt.org/option.php>) \[[@pone.0194176.ref017]\]. Enriched KEGG pathways and GO terms were determined based on their corresponding *P*-values for over-representation against the entire mouse genome. *P* values were calculated using a hypergeometric test and corrected for multiple testing with a Benjamini-Hochberg (GO terms) or Bonferroni (KEGG pathway) correction. A cut-off of 0.05 was applied.

Western blotting {#sec010}
----------------

Briefly, protein samples were separated by 12% SDS-PAGE and then transferred into polyvinylidene difluoride membranes. The membranes were blocked with 5% non-fat milk and then probed overnight at 4°C with anti-GPx1 (1:1000; Abcam). This step was followed by exposure to secondary antibody for 1 h with a 1:2000 dilution of goat anti-rabbit secondary antibody (Cell Signaling Technology, USA). After washing, the membrane was developed with an ECL kit (Amersham Pharmacia Biotechnology, UK) and exposed on a ChemiDoc imaging system (Bio-Rad Laboratories, Hercules, CA). Intensity of bands was quantified using the public domain software, ImageJ software with linear signal tool. Each GPx1 band of each mouse was first normalized with its actin intensity and the SH-GPx1 was then calculated (SH-GPx1/Input-GPx1).

Immunofluorescence staining {#sec011}
---------------------------

Immunofluorescence staining of aortic root sections was performed using rabbit anti-mouse GPx1 antibody to observe the intensity of GPx1 in the aortic roots. Briefly, air-dried cryostat sections (6 μm thickness) of aortic root were fixed with the pre-cooled acetone for 10 min and rinsed with 1× phosphate buffered saline (PBS) three times. Non-specific staining was blocked by incubation with 5% goat serum in 1× PBS for 30 min followed by incubation of anti-GPx1 antibody overnight at 4°C in a 1:200 dilution. After rinsing with 1× PBS, sections were incubated with Alexa 488 anti-rabbit secondary antibody (Invitrogen Molecular Probes, UK) for 1 h while nuclei were stained with DAPI in the mounting agent (Invitrogen Molecular Probes). Microscopic examination was performed on an Olympus IX-83 inverted fluorescence microscope (Olympus, Tokyo, Japan). Images were acquired by a monochrome CCD camera using CellSens software (Olympus, Tokyo, Japan).

Glutathione activities determination {#sec012}
------------------------------------

A commercially available glutathione peroxidase (GPx) assay kit (Cayman Chemical Company) was used to measure plasma GPx activity according to the manufacturer's instructions. Glutathione (GSH) and total GSH were measured using GSH colorimetric assay (BioVision Incorporated, CA, USA). Oxidised glutathione/glutathione disulfide (GSSG) was calculated by subtraction of GSH from total GSH.

Lipid peroxidation determination {#sec013}
--------------------------------

Malondialdehyde (MDA) is a product of lipid peroxidation. Therefore, lipid peroxidation was determined by measuring MDA concentration in mice plasma using a thiobarbituric acid reactive substances (TBARS) assay kit (Cayman Chemical Company).

Statistical analysis {#sec014}
--------------------

All data are presented as mean ± SEM. The non-parametric Mann Whitney test was used to compare variables between two groups. Statistical significance was determined at a level of *P* \< 0.05. Statistical analysis was performed with GraphPad Prism 5.0 software.

Results {#sec015}
=======

H~2~S reduced body weight gain and aortic plaque area in ApoE KO mice {#sec016}
---------------------------------------------------------------------

All ApoE KO mice were first fed with an atherogenic diet for 4 weeks. Their body weight gain decreased in the first week but subsequently returned to normal and remained stable. The mice were then divided into the vehicle-control group and H~2~S-treated group. The body weight gain in the H~2~S group was significantly reduced after H~2~S treatment, whereas the control group body weight remained similar over the whole period of treatment ([Fig 1A](#pone.0194176.g001){ref-type="fig"}). The H~2~S-treated mice had about 5% body weight loss after 4 weeks of H~2~S treatment ([Fig 1B](#pone.0194176.g001){ref-type="fig"}). To demonstrate whether GYY4137 treatment could account for food consumption and thus body weight gain, food uptake by both group mice was measured. It found that GYY4137 treatment did not affect the food consumption ([S2 Table](#pone.0194176.s004){ref-type="supplementary-material"}). In addition, after the H~2~S treatment, the aortic roots were sectioned and stained with lipids using oil red O, which stains atherosclerotic plaques a red colour. There was no red staining in WT mice, and little staining seen in the atherogenic diet-fed ApoE KO mice before treatment ([Fig 1C](#pone.0194176.g001){ref-type="fig"}). After treatment, comparing the size of plaques in the two groups, the control group of mice had a larger plaque size in the aortic root ([Fig 1D](#pone.0194176.g001){ref-type="fig"}) and the oil red O staining was widely observed in the histological result ([Fig 1C](#pone.0194176.g001){ref-type="fig"}). In contrast, the plaque size of H~2~S-treated mice was significantly diminished by 30% ([Fig 1C and 1D](#pone.0194176.g001){ref-type="fig"}), indicating the retardation of the atherosclerotic response in the mice by H~2~S treatment.

![H~2~S administration in ApoE KO mice can reduce body weight gain and atherosclerotic plaque area.\
ApoE KO mice were first fed an atherogenic diet for 4 weeks before H~2~S treatment and then randomly divided into two groups: (i) ApoE KO + saline (0.1 mL per day, i.p.) for 4 weeks and (ii) ApoE KO + H~2~S donor (133 μmol per kg per day, i.p.) for 4 weeks. (A) During the treatment, the body weight of mice was measured weekly and the weight gain per week was calculated. Body weight was lost in mice treated with H~2~S in the first week, whereas the control group had no significant change in weight. Data represent mean ± SEM (*n* = 6--12). (B) The body weight (± SD) was compared before treatment and after 4-weeks of treated in both groups of mice (*n* = 6--12). H~2~S-treated ApoE KO mice were shown to have significant body weight loss after the H~2~S treatment. (C) After treatment, the aortic root was sectioned and stained with oil red O for lipids. H~2~S-treated ApoE KO mice showed reduced lesion area (appearing as red colour in the aortic root) as compared to the saline control group. It was also compared to the ApoE KO mice before H~2~S treatment and the WT C57BL/6J mice, which showed few lesions and no lesions in the aortic root, respectively. (D) The plaque size was quantified as percentage area of red staining in the aortic root. Values are means ± SEM, *n* = 6. The groups were significantly different from each other according to the Mann Whitney test, *P* \< 0.05.](pone.0194176.g001){#pone.0194176.g001}

Identification and characterisation of S-sulfhydrated proteins in aorta {#sec017}
-----------------------------------------------------------------------

The modified approach for the biotin switch method for detecting endogenous and exogenous H~2~S revealed a total of 70 significant proteins (*P* values \< 0.05), corresponding to different *S*-sulfhydrated proteins identified using tandem mass spectrometry ([Table 1](#pone.0194176.t001){ref-type="table"}). For the 70 identified and *S*-sulfhydrated proteins, GO analysis showed that 38.6% of the identified proteins were involved in oxidation-reduction processes. Other biological processes involved transport (17.1%), metabolic process (17.1%), tricarboxylic acid cycle (TCA; 14.3%), lipid metabolic process (12.9%), fatty acid metabolic process (11.4%), response to oxidative stress (8.6%) and negative regulation of apoptotic process (8.6%) ([Fig 2A](#pone.0194176.g002){ref-type="fig"}). In regard to molecular function, the identified proteins are responsible for protein binding (35.9%), ion binding (25.0%), nucleotide binding (23.4%), lipid binding (12.5%), enzyme regulator activity (3.1%) and also antioxidant activity (1.6%) ([Fig 2B](#pone.0194176.g002){ref-type="fig"}).

![Gene ontology (GO) analysis of *S*-sulfhydrated aortic proteins.\
The proteins were analysed in terms of (A) GO biological process and (B) GO molecular function of proteins.](pone.0194176.g002){#pone.0194176.g002}
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###### Identified *S*-sulfhydrated proteins from aorta of ApoE KO mice treated with H~2~S.

![](pone.0194176.t001){#pone.0194176.t001g}

  No.   Accession   ID      Protein                                                                          MW \[kDa\]   pI     Score   No. of Peptides   Coverage \[%\]
  ----- ----------- ------- -------------------------------------------------------------------------------- ------------ ------ ------- ----------------- ----------------
  1     P60710      ACTB    Actin, cytoplasmic 1                                                             41.7         5.3    871.6   13                43.2
  2     P63268      ACTH    Actin, gamma-enteric smooth muscle                                               41.8         5.3    702.6   13                43.9
  3     P10605      CATB    Cathepsin B                                                                      37.3         5.6    520.1   8                 20.9
  4     Q8BWT1      THIM    3-ketoacyl-CoA thiolase, mitochondrial                                           41.8         8.3    508.7   10                27
  5     Q9DBJ1      PGAM1   Phosphoglycerate mutase 1                                                        28.8         6.7    447.4   7                 32.3
  6     Q9DCW4      ETFB    Electron transfer flavoprotein subunit beta                                      27.6         8.2    442.5   6                 34.5
  7     Q8BFZ3      ACTBL   Beta-actin-like protein 2                                                        42.0         5.3    420.7   7                 20.5
  8     P17742      PPIA    Peptidyl-prolyl *cis*-*trans* isomerase A                                        18.0         7.7    366.5   7                 43.9
  9     P07356      ANXA2   Annexin A2                                                                       38.7         7.5    348.5   5                 22.4
  10    P16015      CAH3    Carbonic anhydrase 3                                                             29.3         6.9    314.6   6                 30.8
  11    Q05816      FABP5   Fatty acid-binding protein, epidermal                                            15.1         6.1    310     5                 52.6
  12    P05064      ALDOA   Fructose-bisphosphate aldolase A                                                 39.3         8.3    309.1   6                 20.3
  13    P62962      PROF1   Profilin-1                                                                       14.9         8.5    304.3   5                 40.0
  14    P35486      ODPA    Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial   43.2         8.5    295.8   6                 16.9
  15    O88569      ROA2    Heterogeneous nuclear ribonucleoproteins A2/B1                                   37.4         9.0    294.4   4                 19.3
  16    Q9CZU6      CISY    Citrate synthase, mitochondrial                                                  51.7         8.7    294.1   6                 16.8
  17    P04117      FABP4   Fatty acid-binding protein, adipocyte                                            14.6         8.5    284.8   4                 26.5
  18    P01942      HBA     Hemoglobin subunit alpha                                                         15.1         8.0    277.8   4                 34.5
  19    P97429      ANXA4   Annexin A4                                                                       35.9         5.4    271.9   6                 22.9
  20    P19783      COX41   Cytochrome *c* oxidase subunit 4 isoform 1, mitochondrial                        19.5         9.3    271.2   6                 28.4
  21    Q8K1Z0      COQ9    Ubiquinone biosynthesis protein COQ9, mitochondrial                              35.1         5.6    270.5   3                 18.2
  22    Q9WVA4      TAGL2   Transgelin-2                                                                     22.4         8.4    257.2   4                 28.1
  23    Q01768      NDKB    Nucleoside diphosphate kinase B                                                  17.4         7.0    257.0   6                 42.1
  24    P54071      IDHP    Isocitrate dehydrogenase \[NADP\], mitochondrial                                 50.9         8.9    253.9   6                 15.3
  25    Q9D6R2      IDH3A   Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial                    39.6         6.3    248.2   6                 17.2
  26    P70404      IDHG1   Isocitrate dehydrogenase \[NAD\] subunit gamma 1, mitochondrial                  42.8         9.2    245.1   4                 14.0
  27    P51174      ACADL   Long-chain specific acyl-CoA dehydrogenase, mitochondrial                        47.9         8.5    244.3   6                 17.0
  28    P20152      VIME    Vimentin                                                                         53.7         5.1    234.3   5                 16.1
  29    Q9D051      ODPB    Pyruvate dehydrogenase E1 component subunit beta, mitochondrial                  38.9         6.4    228.5   5                 25.6
  30    Q8BH95      ECHM    Enoyl-CoA hydratase, mitochondrial                                               31.5         8.8    219.3   3                 15.2
  31    P14152      MDHC    Malate dehydrogenase, cytoplasmic                                                36.5         6.2    214.2   5                 18.9
  32    Q7TMF3      NDUAC   NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 12                  17.1         9.4    213.9   5                 45.5
  33    P48036      ANXA5   Annexin A5                                                                       35.7         4.8    212.5   5                 22.3
  34    P10649      GSTM1   Glutathione *S*-transferase Mu 1                                                 26.0         7.7    208.6   5                 25.2
  35    Q99LY9      NDUS5   NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 5                          12.6         9.1    207.3   4                 46.2
  36    P08249      MDHM    Malate dehydrogenase, mitochondrial                                              35.6         8.9    205.3   4                 16.0
  37    O08756      HCD2    3-hydroxyacyl-CoA dehydrogenase type-2                                           27.4         8.5    201.2   4                 19.9
  38    Q61425      HCDH    Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial                              34.4         8.8    196.2   4                 10.8
  39    Q9CZ13      QCR1    Cytochrome *b-c*1 complex subunit 1, mitochondrial                               52.8         5.8    195.7   4                 14.6
  40    P10107      ANXA1   Annexin A1                                                                       38.7         7.0    193.0   4                 13.6
  41    P09671      SODM    Superoxide dismutase \[Mn\], mitochondrial                                       24.6         8.8    176.3   3                 19.8
  42    P02088      HBB1    Hemoglobin subunit beta-1                                                        15.8         7.1    156.4   3                 21.8
  43    P99024      TBB5    Tubulin beta-5 chain                                                             49.6         4.8    156.1   5                 11.9
  44    Q9CR61      NDUB7   NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 7                    16.3         8.4    153.1   3                 38.0
  45    O08807      PRDX4   Peroxiredoxin-4                                                                  31.0         6.7    149.7   3                 11.7
  46    Q9Z2I9      SUCB1   Succinyl-CoA ligase \[ADP-forming\] subunit beta, mitochondrial                  50.1         6.6    148.0   4                 9.7
  47    Q9D0M3      CY1     Cytochrome *c*1, heme protein, mitochondrial                                     35.3         9.2    142.9   3                 15.4
  48    P13707      GPDA    Glycerol-3-phosphate dehydrogenase \[NAD(+)\], cytoplasmic                       37.5         6.8    138     4                 12.0
  49    O35855      BCAT2   Branched-chain-amino-acid aminotransferase, mitochondrial                        44.1         8.6    137.8   4                 14.0
  50    P14131      RS16    40S ribosomal protein S16                                                        16.4         10.2   133.2   4                 24.7
  51    Q99JY0      ECHB    Trifunctional enzyme subunit beta, mitochondrial                                 51.4         9.4    133.0   4                 9.9
  52    P67778      PHB     Prohibitin                                                                       29.8         5.6    131.5   3                 16.2
  53    Q9DC69      NDUA9   NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 9, mitochondrial    42.5         9.7    131.2   3                 8.0
  54    P09528      FRIH    Ferritin heavy chain                                                             21.1         5.5    128.5   3                 15.4
  55    Q9CQI6      COTL1   Coactosin-like protein                                                           15.9         5.2    128     4                 23.9
  56    P42125      ECI1    Enoyl-CoA delta isomerase 1, mitochondrial                                       32.2         9.1    127.1   3                 9.3
  57    Q9R0P5      DEST    Destrin                                                                          18.5         8.1    124.4   3                 18.2
  58    P15105      GLNA    Glutamine synthetase                                                             42.1         6.6    123.5   3                 12.3
  59    Q8BFR5      EFTU    Elongation factor Tu, mitochondrial                                              49.5         7.2    117.7   3                 10.0
  60    P16110      LEG3    Galectin-3                                                                       27.5         8.5    115.5   3                 12.1
  61    P14206      RSSA    40S ribosomal protein SA                                                         32.8         4.8    113.8   4                 15.3
  62    Q9DCJ5      NDUA8   NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 8                   20.0         8.8    110.1   3                 18.6
  63    Q9JII6      AK1A1   Alcohol dehydrogenase \[NADP(+)\]                                                36.6         6.9    97.3    3                 6.2
  64    P97351      RS3A    40S ribosomal protein S3a                                                        29.9         9.8    92.5    3                 14.8
  65    P45952      ACADM   Medium-chain specific acyl-CoA dehydrogenase, mitochondrial                      46.5         8.6    91.7    3                 5.9
  66    P59999      ARPC4   Actin-related protein 2/3 complex subunit 4                                      19.7         8.5    87.4    3                 22.6
  67    O88844      IDHC    Isocitrate dehydrogenase \[NADP\] cytoplasmic                                    46.6         6.7    85.5    3                 9.4
  68    P35700      PRDX1   Peroxiredoxin-1                                                                  22.2         8.3    81.0    3                 22.6
  69    P61205      ARF3    ADP-ribosylation factor 3                                                        20.6         6.8    80.5    3                 14.9
  70    P11352      GPx1    Glutathione peroxidase 1                                                         22.3         6.7    71.4    3                 17.4

Enrichment analysis of S-sulfhydrated proteins in aorta {#sec018}
-------------------------------------------------------

In the enrichment analysis, biological processes categorised as lipid metabolism (e.g., fatty acid metabolism and oxidation) or energy production and conversion (e.g., TCA cycle) were mainly enriched in the identified protein set ([Fig 3A](#pone.0194176.g003){ref-type="fig"}). For the molecular function, proteins involved in antioxidant activity were enriched the most against the entire mice genome, followed by peroxidase activity ([Fig 3B](#pone.0194176.g003){ref-type="fig"}). In terms of protein class, hydratase was augmented the most in the identified proteins (\~ 50-fold). Others included peroxidase (\~38-fold), actin-related proteins (\~33-fold) and dehydrogenase (\~23-fold) ([Fig 3C](#pone.0194176.g003){ref-type="fig"}).

![Gene ontology (GO) enrichment analysis for *S*-sulfhydrated proteins in mice aorta.\
Enriched GO terms for (A) biological process, (B) molecular function and (C) protein class were determined based on their corresponding *P* values for over-representation against the mice entire genome.](pone.0194176.g003){#pone.0194176.g003}

Furthermore, the enrichment of identified *S*-sulfhyrated proteins was observed in 17 molecular pathways by the pathway enrichment analysis using KEGG (WEBGESTALT) ([Fig 4A](#pone.0194176.g004){ref-type="fig"}). Out of 70 sulfhydrated proteins, 5 were involved in lipid metabolism pathways, including hydroxyacyl-coenzyme A dehydrogenase (HADH), acyl-CoA dehydrogenases, long chain (ACADL), enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) acyl-CoA dehydrogenase, medium chain (ACADM) and enoyl-CoA delta isomerase 1 (ECI1). Also found to be enriched were proteins involved in valine/leucine/isoleucine (e.g., ACADM and branched-chain-amino-acid aminotransferase, mitochondrial, BCAT2) and GSH metabolism (e.g., GPx1 and glutathione *S*-transferase Mu 1, GSTM1). The peroxisome and peroxisome proliferator-activated receptors (PPARs) signalling pathway was also found to be augmented and could play a role in redox signalling and lipid homoeostasis. Enrichment of identified *S*-sulfhydrated proteins was also observed in the TCA cycle, pyruvate metabolism and glycolysis ([Fig 4A](#pone.0194176.g004){ref-type="fig"}). Most of the enriched pathways were metabolic pathways involved in energy production and conversion. Other pathways of lipid metabolism and amino acid metabolism were also observed to be elevated ([Fig 4B](#pone.0194176.g004){ref-type="fig"}), indicating that H~2~S appears to mitigate atherosclerosis through regulation of lipid metabolism and anti-oxidative response to stimulus.

![Pathway enrichment analyses for *S*-sulfhydrated proteins in mice aorta.\
(A) 19 KEGG pathways were found to be enriched, and the ratio of enrichment of each pathway was revealed in the identified protein set of *S*-sulfhydration with their corresponding *P* values. (B) The enriched KEGG pathways were categorised and presented as percentage that the largest group of the proteins were constituted by global metabolism. Lipid metabolism and amino acid metabolism were also major contributors, whereas a number of pathways were classified as 'others'.](pone.0194176.g004){#pone.0194176.g004}

Protein S-sulfhydration of aortic proteins {#sec019}
------------------------------------------

H~2~S signalling through *S*-sulfhydration involves H~2~S altering functions of proteins by modification on cysteine residues in proteins through the formation of a persulfide (--SSH) bond \[[@pone.0194176.ref018]\]. A modified biotin switch method, a way to detect *S*-sulfhydrated proteins, was used to determine the pattern of *S*-sulfhydration of aortic proteins in control and H~2~S-treated mice. The results indicated that H~2~S treatment induced an increase in *S*-sulfhydration of aorta proteins as compared to the controls ([Fig 5A](#pone.0194176.g005){ref-type="fig"}). The *S*-sulfhydrated proteins appeared as bands on western blotting from low-molecular-weight proteins to high-molecular-weight proteins ([Fig 5B](#pone.0194176.g005){ref-type="fig"}), including the band corresponding to GPx1, which is involved in cellular response to stress during atherosclerosis. Western blot analysis of aorta lysate revealed a band corresponding to GPx1 at 22 kDa as a putative target for *S*-sulfhydration ([Fig 5C](#pone.0194176.g005){ref-type="fig"}). This was confirmed by immunoprecipitation of the aorta proteins with anti-GPx1 antibody on both control and H~2~S-treated aortas. We observed that endogenous GPx1 *S*-sulfhydration increased by 1.4-fold upon H~2~S treatment ([Fig 5C](#pone.0194176.g005){ref-type="fig"}), suggesting that H~2~S can *S*-sulfhydrate GPx1 proteins and that *S*-sulfhydration was enhanced after H~2~S treatment.

![H~2~S effects on *S*-sulfhydrated proteins and GPx1 *S*-sulfhydration.\
(A) Gel staining of biotinylated proteins in control and H~2~S-treated ApoE KO mice. (B) Detection of *S*-sulfhydrated proteins by western blot analysis in control and H~2~S-treated ApoE KO mice. There was an increase of *S*-sulfhydration upon H~2~S treatment. (C) Representative blot image of immunoprecipitated GPx1 from control and H~2~S-treated mice aorta was extracted from the blot of first mice pair (control and H~2~S-treated mice). H~2~S sulfhydrated GPx1 overexpressed in the aorta lysate of H~2~S-treated mice and the band intensities were quantified using ImageJ. SH--GPx1, *S*-sulfhydrated GPx1; input-GPx1, total GPx1. Comparison between groups by Mann Whitney test, *P* \< 0.05; *n* = 4 for each group.](pone.0194176.g005){#pone.0194176.g005}

S-sulfhydration reduced lipid peroxidation and enhanced GSH synthesis {#sec020}
---------------------------------------------------------------------

To confirm the effect of *S*-sulfhydration on aortic tissue, we examined the expression and activity of GPx1. GPx1 was abundantly expressed as green fluorescence signal in the aortic root of H~2~S-treated mice, whereas only minimal green fluorescence was observed in the control aortic sections ([Fig 6A](#pone.0194176.g006){ref-type="fig"}). In addition, the plasma GPx1 activity also revealed a higher level in H~2~S-treated mice, that was about 2.4-fold higher than the activity observed in control mice ([Fig 6B](#pone.0194176.g006){ref-type="fig"}). These results show that *S*-sulfhydration can enhance the level of GPx1 and thus its activity. It is known that GPx is an enzyme family with peroxidase activity whose main biological role is to protect the organism from oxidative damage. It converts toxic lipid peroxides into inert alcohols and reduces free hydrogen peroxide to water by using reduced GSH. Thus, we continued to examine the effect of H~2~S on MDA and GSH contents to determine lipid peroxides production and GSH synthesis. As shown in [Fig 6C](#pone.0194176.g006){ref-type="fig"}, the level of MDA, the by-product of lipid peroxidation, was increased in the mice without H~2~S treatment but was significantly reduced by 43% after H~2~S administration ([Fig 6C](#pone.0194176.g006){ref-type="fig"}), suggesting that H~2~S facilitates clearance of reactive oxygen species (ROS) such as free radicals and thus protects the cells from damage. In parallel, to further investigate the level of GSH in relation to H~2~S supplementation, plasma concentration of total GSH, reduced GSH (GSH) and oxidised GSH (GSSG) were measured in both groups of mice ([Fig 6D](#pone.0194176.g006){ref-type="fig"}). The total GSH did not differ much in either group of mice, although H~2~S-treated mice had slightly higher total GSH than the control mice. Control mice had a higher GSSG level and lower GSH level, indicating accumulation of GSSG and exposure of oxidative stress in cells. However, this relationship was reversed by H~2~S treatment, as revealed by a decreased level of GSSG and an elevation in GSH level by about two times in H~2~S-treated mice in comparison to its level in control mice ([Fig 6D](#pone.0194176.g006){ref-type="fig"}). Consistently, results showed that the GSH/GSSG ratio was increased by 2.3-fold in H~2~S-treated mice, as compared to that in the control group ([Fig 6E](#pone.0194176.g006){ref-type="fig"}), demonstrating protection of cells from oxidative damage upon H~2~S treatment.

![*S*-sulfhydration enhances anti-oxidative stress responses.\
(A) Immunofluorescence staining of GPx1 in aortic root of ApoE KO mice with or without H~2~S treatment. It showed overexpression of GPx1 in aortic root lesions and intima of aortic root sections after 4 weeks of H~2~S administration. GPx1 appeared as green fluorescence, whereas cell nuclei are represented by blue fluorescence of DAPI. The images are shown at 10× magnification. The GPx1 signals in aortic roots were quantified by ImageJ software. (B) H~2~S treatment significantly increased plasma GPx activity (oxidation of NADPH to NADP^+^), suggesting inhibition of oxidative damage. (C) Lipid peroxidation was determined by measurement of malondialdehyde (MDA) in plasma. MDA level was reduced in H~2~S-treated mice. (D) Plasma glutathione (GSH) assay significantly showed increase of total GSH and GSH but decreased GSSG, indicating the cells were protected from oxidative damage. (E) Higher ratio of GSH/GSSG in H~2~S treatment group also indicated antioxidant effects of H~2~S. GPx, glutathione peroxidase; GSH, glutathione; GSSG, oxidised glutathione. Values are means ± SEM, *n* = 6. The groups are significantly different from each other by Mann Whitney test, *P* \< 0.05.](pone.0194176.g006){#pone.0194176.g006}

Discussion {#sec021}
==========

H~2~S administration with GYY4137 ameliorated atherosclerosis in the present study. GYY4137 is a slow-releasing donor of H~2~S. It releases H~2~S slowly both in *vitro* and *in vivo* and it just offers about 4--5 nmol per 25 min \[[@pone.0194176.ref013]\]. In this study, plasma H~2~S released from GYY4137 was increased at the first 30 minutes and then returned to normal after 8 hours ([S1 Fig](#pone.0194176.s001){ref-type="supplementary-material"}). In addition, H~2~S was accumulated in liver and kidney very quickly upon GYY4137 treatment and maintained about 2 hours then started to decline to normal after 8 hours of injection, indicating no residue of H~2~S in liver and kidney ([S2 Fig](#pone.0194176.s002){ref-type="supplementary-material"}). All these showed that GYY4137 is a stable H~2~S donor and it has low toxicity which could be used to study regulatory role of H~2~S in animal model with acute diseases.

H~2~S treatment was characterised by loss of body weight and reduction of plaque formation, both of which are consistent with our previous study using CSE overexpression transgenic mice as a model \[[@pone.0194176.ref005]\], and also agrees with other studies \[[@pone.0194176.ref004],[@pone.0194176.ref006]\]. We have identified 70 proteins that are *S*-sulfhydrated to a significant degree from aortic tissue of ApoE KO mice. Functional annotation of the *S*-sulfhydration of aortic proteins reveals a main pathway of lipid metabolism in the development of atherosclerosis. Lipid metabolism is closely linked to the metabolism of carbohydrates, which may be converted to fats. The major aspect of lipid metabolism is involved with fatty acid oxidation to produce energy or the synthesis of lipids. The first step in lipid metabolism is the hydrolysis of the lipid in the cytoplasm to produce glycerol and fatty acids, which then further undergo glycolysis and β-oxidation of fatty acid, respectively. Here we show that H~2~S may regulate glycolysis and fatty acid metabolism through protein *S*-sulfhydration as revealed in our global analysis of *S*-sulfhydrated proteins in mouse aortic tissues. Pathways of glycolysis (e.g., aldolase A, fructose-bisphosphate, ALDOA and phosphoglycerate mutase 1, PGAM1) and fatty acid metabolism/oxidation (e.g., ACADL and ACADM) were augmented in the over-representation analysis.

Enhanced glycolysis and pentose phosphate pathway could result in increased antioxidant defence, as shown in the human osteosarcoma SAOS-2 cell line with expression of TAp63α \[[@pone.0194176.ref019]\] and in vanadium-treated diabetic rats \[[@pone.0194176.ref020]\] as a result of the generation of reduced GSH, a major scavenger of ROS during the process. A recent study also indicated that the CSE/H~2~S pathway plays an important role in the regulation of glucose production through *S*-sulfhydration of pyruvate carboxylase contributing to gluconeogenesis in the liver \[[@pone.0194176.ref021]\]. In addition, an increase in fatty acid oxidation has been observed to reduce triglyceride content and inflammatory levels, improve insulin sensitivity in adipocytes and reduce endoplasmic reticulum stress and ROS damage in macrophages \[[@pone.0194176.ref022]\]. Another fate of fatty acids after oxidation is the production of shortened fatty acids such as propanoate and acetate, which can then enter the circulation, where they transit directly to the liver and serve in energy production \[[@pone.0194176.ref023]\]. These shortened fatty acids may play an important role in health and disease, in that they help to reduce the risk of inflammatory diseases, type 2 diabetes, obesity, heart disease and other conditions \[[@pone.0194176.ref024]\]. Moreover, shortened fatty acids have also been shown to aid in control of body weight and insulin sensitivity \[[@pone.0194176.ref025]\]. Therefore, augmented propanoate metabolism in the enrichment analysis suggests a lowering of cholesterol level \[[@pone.0194176.ref026]\] and protection against diet-induced obesity \[[@pone.0194176.ref027]\].

Further, the PPAR signalling pathway was also elevated in the *S*-sulfhydrated aortic proteins we studied, and is also involved in lipid homeostasis. Fatty acid binding protein 4, adipocyte (FABP4) and fatty acid binding protein 5, epidermal (FABP5) were identified as *S*-sulfhydrated proteins in the PPAR pathway. These two proteins involved in lipid metabolism by binding to fatty acids through activation of PPARs, which comprise three subtypes: PPARα, PPARδ/β and PPARγ. These receptors are transcription factors that control the peroxisomal β-oxidation pathway of fatty acids through regulation of the acyl-CoA oxidase. Thus, PPARs play an important role in lipid metabolism. Cheng's group demonstrated that PPARδ activated fatty acid oxidation in cultured cardiomyocytes by regulating key genes of fatty acid oxidation \[[@pone.0194176.ref028]\]. PPARδ was shown to act as a regulator of fat burning and was identified as a potential target in the treatment of obesity and its associated disorders \[[@pone.0194176.ref029]\]. In addition, PPAR was sulfhydrated after H~2~S treatment \[[@pone.0194176.ref030]\] and its activation could improve lipid profiles and reduce adiposity \[[@pone.0194176.ref031]\]. In line with this observation, recent evidence has shown that a PPARδ agonist inhibited aortic inflammation and attenuated the progression of pre-established atherosclerosis through reduction of plasma lipids, particularly very low-density and intermediate-density lipoproteins \[[@pone.0194176.ref032]\]. Taken together, all these studies reveal that H~2~S is highly associated with reduced obesity by regulation of glucose and lipid homoeostasis, as supported by a recent study \[[@pone.0194176.ref033]\] and a review \[[@pone.0194176.ref034]\].

In the enrichment analysis, antioxidant activity and peroxidase activity were shown to be enriched. Therefore, GPx1 can be considered as a putative target of *S*-sulfhydration in atherosclerosis. GPx1 is a selenium-dependent enzyme that is ubiquitously expressed and protects cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxides with reduced GSH. As an antioxidant enzyme, GPx1 has been used as a biomarker for cardiovascular risk \[[@pone.0194176.ref035],[@pone.0194176.ref036]\]. It has also been proposed to be a therapeutic target for chronic obstructive pulmonary disease \[[@pone.0194176.ref037]\]. In atherosclerosis, increased oxidative stress is a result of the generation of ROS and increased free-radical production, which may play an important role in the pathogenesis and progression of atherosclerotic plaques. Increased lipid peroxidation also appears to be associated with oxidative stress in atherosclerosis \[[@pone.0194176.ref038]\] and diabetes \[[@pone.0194176.ref039]\]. In the present study, H~2~S *S*-sulfhydrated GPx1 and stimulated its activity in cells and in plasma. With enhanced GPx1 activity and enriched pathways such as GSH metabolism and glycolysis, GSH biosynthesis upregulation plays a critical role in the cellular defence against oxidative stress. GPx1 exerts its antioxidant effect to protect the cells from oxidative damage by reduction of lipid peroxidation and clearance of free radicals in the progression of atherosclerosis. Furthermore, enhanced GSH biosynthesis was found to be closely connected with increased fatty acid oxidation and synthesis \[[@pone.0194176.ref040]\] as well as reduction of body weight, as shown in our previous study \[[@pone.0194176.ref005]\] and another study \[[@pone.0194176.ref041]\].

In conclusion, the present study identified *S*-sulfhydrated proteins in several metabolic pathways. The *S*-sulfhydration level of altered proteins in aorta indicates significant protein modifications that may lead to structural or functional alterations. Protein *S*-sulfhydration in atherosclerosis targets particular enzymes participating in glycolysis, TCA cycle, and fatty acid oxidation, indicating that this post-translational modification may regulate metabolism and mitochondrial bioenergetics. Our results showed that H~2~S has such cardiovascular protective effects as prevention of body weight gain and reduction of atherosclerotic plaque formation through augmentation of lipid metabolism. H~2~S is also mediated by its antioxidant effect via GPx1 *S*-sulfhydration, which causes decreased lipid peroxidation and enhanced GSH biosynthesis. The present proteomics study provides a comprehensive analysis of H~2~S signalling via *S*-sufhydration in response to atherosclerosis.
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###### Plasma concentration of H~2~S in mice administered GYY4137.

Blood was collected at timed intervals after GYY4137 administration and plasma H~2~S concentration was assayed. Values are means ± SEM, *n* = 3.

(TIF)
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Click here for additional data file.

###### H~2~S concentrations in liver and kidney after GYY4137 administration.

Tissues were collected at timed intervals after administration and H~2~S concentration was assayed. Values are means ± SEM, *n* = 3.

(TIF)
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Click here for additional data file.

###### A complete list of data set in this study.
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###### Food uptake per mice per day.
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